Anna Olechowska

Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.

For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.

Results from the largest prospective study of rituximab use in patients with relapsing ANCA-associated vasculitis show that 91.2% of participants achieved remission.

The FSI proved to be at least as effective in predicting fracture risk in children as femoral and total body BMD.

The risk of bone health decline in menopausal women is decreased by intermittent hypoxia in OSA.

Risk of bone health decline in menopausal women is decreased by intermittent hypoxia in OSA.

A new bone assessment evaluates fracture risk in children.

A physician- and patient-based survey revealed differences in treatment goals, patient concerns, and more.

Romosozumab could be a better option than teriparatide for patients at a high risk for fracture.

The US FDA has approved a new fixed-dose and dual-mechanism treatment option for uncontrolled gout.

Diclofenac used at the maximum dos of 150 mg/day was shown to be the most effective NSAID for the treatment of osteoarthritis.